Disease · MONDO_0005212
Comparisons in its trials24
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 24
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) vs VAC Alternating With VI: serious adverse events | 4 of 222 | 11 of 226 | 448 | NCT00354835 | Trial comparisons |
| Regimen I (Chemotherapy, Radiotherapy) vs Regimen II (Chemotherapy, Radiotherapy, Surgery): serious adverse events | 1 of 272 | 1 of 70 | 342 | NCT00075582 | Trial comparisons |
| IMC-A12 vs Temozolomide: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | 89 of 96 | 61 of 70 | 166 | NCT01055314 | Trial comparisons |
| Group 1 (Chemotherapy, Radiation Therapy, Cixutumumab) vs Group 2 (Chemotherapy, Radiation Therapy, Temozolomide): serious adverse events | 79 of 96 | 40 of 70 | 166 | NCT01055314 | Trial comparisons |
| Chemotherapy vs Bevacizumab + Chemotherapy: deaths from any cause | 40 of 79 | 37 of 71 | 150 | NCT00643565 | Trial comparisons |
| Chemotherapy vs Bevacizumab + Chemotherapy: serious adverse events | 68 of 79 | 66 of 71 | 150 | NCT00643565 | Trial comparisons |
| Regimen A vs Regimen B: serious adverse events | 35 of 44 | 32 of 42 | 86 | NCT01222715 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: Toxicity | 6 of 6 | 24 of 26 | 32 | NCT00923351 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: deaths from any cause | 0 of 6 | 1 of 26 | 32 | NCT00923351 | Trial comparisons |
| Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: serious adverse events | 6 of 6 | 12 of 26 | 32 | NCT00923351 | Trial comparisons |
Arm A - Participants Who Did Not Receive rhIL-7 vs Arm B - Participants Who Received rhIL-7: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay | 0 of 5 | 15 of 26 | 31 | NCT00923351 | Trial comparisons |
| Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 vs Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2: Phase 1: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE) | 2 of 5 | 12 of 18 | 23 | NCT03245151 | Trial comparisons |
| Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2 vs Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 5 of 5 | 18 of 18 | 23 | NCT03245151 | Trial comparisons |
| Group 1 Relapsed/Refractory Rhabdomyosarcoma vs Group 2 Relapsed/Refractory Wilms Tumor: serious adverse events | 4 of 10 | 3 of 10 | 20 | NCT01502410 | Trial comparisons |
| Dose Finding - Level 0 vs Dose Finding - Level 1: Number of Participants With Dose Limiting Toxicity Adverse Events - Dose Finding Part | 1 of 8 | 2 of 9 | 17 | NCT02372006 | Trial comparisons |
| Dose Finding - Level 0 vs Dose Finding - Level 1: Number of Participants With Objective Response - Dose Finding Part | 0 of 8 | 0 of 9 | 17 | NCT02372006 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | 1 of 10 | 0 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Laboratory Abnormalities | 0 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Physical Examination Abnormalities | 6 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: deaths from any cause | 6 of 10 | 2 of 3 | 13 | NCT05093322 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005212/comparisons